What Is the Impact of the Novel Coronavirus and the Vaccination on Guillain–Barre Syndrome?
Molecular Neurobiology - Trang 1-16 - 2023
Tóm tắt
The COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has resulted in devastating medical and economic consequences worldwide over the past 3 years. As the pandemic enters a new stage, it is essential to consider the potential impact on rare diseases such as Guillain–Barre syndrome (GBS), which has been intimately associated with COVID-19 since the first COVID-19-related GBS case was reported in January 2020. There are notable differences between COVID-19-related GBS and GBS without COVID-19 in terms of diagnostic types and clinical manifestations. Furthermore, with the widespread administration of COVID-19 vaccines, there have been reports of GBS occurring shortly after vaccination, which requires close attention despite its rarity. This review also explores the vaccines associated with heightened GBS risks, offering insights that may guide vaccination policies and clinical practice. To provide a visual summary of these findings, we have included a graphical abstract. This article will discuss the characteristic manifestations of GBS patients after being positive for the novel coronavirus and the safety of several COVID-19 vaccines. Firstly, this article comprehensively expounds and discusses the epidemiological aspects of novel coronavirus–related GBS. For example, from the perspective of the same population, the expected incidence of GBS in the COVID-19-positive population (persons/100,000 persons/ year) is about 43 times that of the COVID-19-negative population, and the incidence of GBS is significantly increased. Secondly, the clinical characteristics of COVID-19-negative GBS patients and SARS-CoV-2-GBS (SC2-GBS) patients were summarized and compared. Thirdly, this article reviews GBS cases in the current adverse events after COVID-19 vaccination and analyzes and discusses from multiple perspectives, such as the incidence of GBS events, the age proportion of patients, and the interval of onset
Tài liệu tham khảo
Dalakas MC (2020) Guillain-Barré syndrome: the first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. Neurol Neuroimmunol Neuroinflamm 7(5)
Willison HJ, Jacobs BC, van Doorn PA (2016) Guillain-Barré syndrome. Lancet 388(10045):717–727
Lapostolle F, Schneider E, Vianu I et al (2020) Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study. Intern Emerg Med 15(5):813–817
Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E et al (2020) Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. Neurology 95(8):e1060–e1070
Lechien JR, Chiesa-Estomba CM, Place S et al (2020) Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med 288(3):335–344
Khedr EM, Abo-Elfetoh N, Deaf E et al (2021) Surveillance study of acute neurological manifestations among 439 Egyptian patients with COVID-19 in Assiut and Aswan university hospitals. Neuroepidemiology 55(2):109–118
Mao L, Jin H, Wang M et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan. China JAMA Neurol 77(6):683–690
Filosto M, CottiPiccinelli S, Gazzina S et al (2021) Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry 92(7):751–756
Xu E, Xie Y, Al-Aly Z (2022) Long-term neurologic outcomes of COVID-19. Nat Med. https://doi.org/10.1038/s41591-022-02001-z
Kevadiya BD, Machhi J, Herskovitz J et al (2021) Diagnostics for SARS-CoV-2 infections. Nat Mater 20(5):593–605
Patone M, Handunnetthi L, Saatci D et al (2021) Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med 27(12):2144–2153
Ray STJ, Abdel-Mannan O, Sa M et al (2021) Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study. Lancet Child Adolesc Health 5(9):631–641
LaRovere KL, Riggs BJ, Poussaint TY et al (2021) Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome. JAMA Neurol 78(5):536–547
Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y (2021) The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 20(4):102792
Khan F, Sharma P, Pandey S et al (2021) COVID-19-associated Guillain-Barre syndrome: postinfectious alone or neuroinvasive too? J Med Virol 93(10):6045–6049
Zhao H, Shen D, Zhou H, Liu J, Chen S (2020) Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 19(5):383–384
Finsterer J, Scorza FA (2021) Guillain-Barre syndrome in 220 patients with COVID-19. Egypt J Neurol Psychiatr Neurosurg 57(1):55
Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M (2021) Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol 268(4):1133–1170
Uncini A, Vallat JM, Jacobs BC (2020) Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psychiatry 91(10):1105–1110
Carrillo-Larco RM, Altez-Fernandez C, Ravaglia S, Vizcarra JA (2020) COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports. Wellcome Open Res 5:107
Manganotti P, Bellavita G, D’Acunto L et al (2021) Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillain-Barré syndrome and polyneuritis cranialis in COVID-19 patients: a case series. J Med Virol 93(2):766–774
Fredrich S, Greenberg BM, Hatanpaa KJ (2021) Neurological infections in 2020: COVID-19 takes centre stage. Lancet Neurol 20(1):17–18
Rosenblum HG, Hadler SC, Moulia D et al (2021) Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the Advisory Committee on Immunization Practices - United States, July 2021. MMWR Morb Mortal Wkly Rep 70(32):1094–1099
David SS, Potasman I, Rahamim-Cohen D (2021) Rate of recurrent Guillain-Barré syndrome after mRNA COVID-19 vaccine BNT162b2. JAMA Neurol 78(11):1409–1411
Woo EJ, Mba-Jonas A, Dimova RB, Alimchandani M, Zinderman CE, Nair N (2021) Association of receipt of the Ad26.COV2S COVID-19 vaccine with presumptive Guillain-Barré syndrome, February-July 2021. Jama 326(16):1606–1613
Li X, Raventós B, Roel E et al (2022) Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. BMJ 376:e068373
Rodríguez Y, Rojas M, Beltrán S et al (2022) Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. J Autoimmun 132:102898
Allen CM, Ramsamy S, Tarr AW et al (2021) Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol 90(2):315–318
van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA (2014) Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 10(8):469–482
Shui IM, Rett MD, Weintraub E et al (2012) Guillain-Barré syndrome incidence in a large United States cohort (2000–2009). Neuroepidemiology 39(2):109–115
Sejvar JJ, Baughman AL, Wise M, Morgan OW (2011) Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 36(2):123–133
Yuki N, Hartung HP (2012) Guillain-Barré syndrome. N Engl J Med 366(24):2294–2304
Vakili K, Fathi M, Hajiesmaeili M et al (2021) Neurological symptoms, comorbidities, and complications of COVID-19: a literature review and meta-analysis of observational studies. Eur Neurol 84(5):307–324
Mussinatto I, Benevenuta C, Caci A et al (2022) Possible association between Guillain-Barré syndrome and SARS-CoV-2 infection in children: a case report and literature review. Exp Ther Med 24(1):462
Rahimi K (2020) Guillain-Barre syndrome during COVID-19 pandemic: an overview of the reports. Neurol Sci 41(11):3149–3156
Paliwal VK, Garg RK, Gupta A, Tejan N (2020) Neuromuscular presentations in patients with COVID-19. Neurol Sci 41(11):3039–3056
Shao SC, Wang CH, Chang KC, Hung MJ, Chen HY, Liao SC (2021) Guillain-Barré syndrome associated with COVID-19 vaccination. Emerg Infect Dis 27(12):3175–3178
Keddie S, Pakpoor J, Mousele C et al (2021) Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain 144(2):682–693
Taga A, Lauria G (2022) COVID-19 and the peripheral nervous system. A 2-year review from the pandemic to the vaccine era. J Peripher Nerv Syst 27(1):4–30
Hanson KE, Goddard K, Lewis N et al (2022) Incidence of Guillain-Barré syndrome after COVID-19 vaccination in the vaccine safety datalink. JAMA Netw Open 5(4):e228879
how-its-designed.; Available from: https://www.janssencovid19vaccine.com/hcp/how-its-designed.html
Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N (2022) COVID-19 vaccines mix-and-match: the concept, the efficacy and the doubts. J Med Virol 94(4):1294–1299
Oo WM, Giri P, de Souza A (2021) AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: a causal link? J Neuroimmunol 360:577719
Frontera JA, Tamborska AA, Doheim MF et al (2022) Neurological events reported after COVID-19 vaccines: an analysis of VAERS. Ann Neurol 91(6):756–771
Bellucci M, Germano F, Grisanti S et al (2022) Case report: Post-COVID-19 vaccine recurrence of Guillain-Barré syndrome following an antecedent parainfectious COVID-19-related GBS. Front Immunol 13:894872
United States Department of Health and Human Services (DHHS), PHSP, Centers for Disease Control (CDC) / Food and Drug Administration (FDA), Vaccine Adverse Event Reporting System (VAERS). CDC WONDER On-line Database. 1990 - 09/16/2022; Available from: http://wonder.cdc.gov/vaers.html
Li X, Ostropolets A, Makadia R et al (2021) Characterising the background incidence rates of adverse events of special interest for COVID-19 vaccines in eight countries: multinational network cohort study. BMJ 373:n1435
Li C, Lee A, Grigoryan L et al (2022) Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat Immunol 23(4):543–555
Karikó K, Muramatsu H, Welsh FA et al (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16(11):1833–1840
Klein NP, Lewis N, Goddard K et al (2021) Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA 326(14):1390–1399
Mahroum N, Lavine N, Ohayon A et al (2022) COVID-19 vaccination and the rate of immune and autoimmune adverse events following immunization: insights from a narrative literature review. Front Immunol 13:872683
Finsterer J, Scorza FA, Scorza CA (2021) Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients. Clinics (Sao Paulo) 76:e3286
Takahashi K, Tomoda Y, Kadena S, Kanbayashi T, Kobayashi S, Kato R (2022) Guillain-Barré syndrome after BNT162b2 (Pfizer-BioNTec) vaccination. QJM 115(5):331–333
Voysey M, Clemens SAC, Madhi SA et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269):99–111
European Medicines agency (EMA). Available from: https://www.ema.europa.eu/en
Agency EM (2021) Meeting Highlights From the Pharmacovigilance Risk Assessment Committee (PRAC). Available at:. Available from: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-july-2021
Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC (2014) Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain 137(Pt 1):33–43
Iadecola C, Anrather J, Kamel H (2020) Effects of COVID-19 on the nervous system. Cell 183(1):16-27.e1
Karimi N, Boostani R, Fatehi F et al (2021) Guillain-Barre syndrome and COVID-19 vaccine: a report of nine patients. Basic Clin Neurosci 12(5):703–710
Tabatabaee S, Rezania F, Alwedaie SMJ et al (2022) Post COVID-19 vaccination Guillain-Barre syndrome: three cases. Hum Vaccin Immunother 18(5):2045153
Nelson KE (2012) Invited commentary: Influenza vaccine and Guillain-Barre syndrome–is there a risk? Am J Epidemiol 175(11):1129–1132
Goodman JL, Grabenstein JD, Braun MM (2020) Answering key questions about COVID-19 vaccines. JAMA 324(20):2027–2028
Márquez Loza AM, Holroyd KB, Johnson SA, Pilgrim DM, Amato AA (2021) Guillain- Barré Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial: Temporal Associations Do Not Imply Causality. Neurology. https://doi.org/10.1212/wnl.0000000000011881
McKean N, Chircop C (2021) Guillain-Barré syndrome after COVID-19 vaccination. BMJ Case Rep 14(7). https://doi.org/10.1136/bcr-2021-244125
Administration FAD (2021) Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration. Janssen COVID-19 vaccine emergency use authorization. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/Janssen-covid-19-vaccine
Ling L, Bagshaw SM, Villeneuve PM (2021) Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome. CMAJ 193(46):E1766-e1769
Rajabally YA, Durand MC, Mitchell J, Orlikowski D, Nicolas G (2015) Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice? J Neurol Neurosurg Psychiatry 86(1):115–119
Elzouki AN, Osman MAM, Ahmed MAE et al (2021) COVID-19 infection presented as Guillain-Barre Syndrome: report of two new cases and review of 116 reported cases and case series. Travel Med Infect Dis 44:102169
Uncini A, Foresti C, Frigeni B et al (2021) Electrophysiological features of acute inflammatory demyelinating polyneuropathy associated with SARS-CoV-2 infection. Neurophysiol Clin 51(2):183–191
Wijdicks EF, Klein CJ (2017) Guillain-Barré Syndrome. Mayo Clin Proc 92(3):467–479
Galassi G, Marchioni A (2022) Acute neuromuscular syndromes with respiratory failure during COVID-19 pandemic: where we stand and challenges ahead. J Clin Neurosci 101:264–275
Toscano G, Palmerini F, Ravaglia S et al (2020) Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med 382(26):2574–2576
Sansone P, Giaccari LG, Aurilio C, Coppolino F, Esposito V, Fiore M, Paladini A, Passavanti MB, Pota V, Pace MC (2021) Post-Infectious Guillain-Barré Syndrome Related to SARS-CoV-2 Infection: A Systematic Review. Life (Basel) 11(2). https://doi.org/10.3390/life11020167
Herman C, Mayer K, Sarwal A (2020) Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19. Neurology 95(2):77–84
Fragiel M, Miró Ò, Llorens P et al (2021) Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19. Ann Neurol 89(3):598–603
Caress JB, Castoro RJ, Simmons Z et al (2020) COVID-19-associated Guillain-Barré syndrome: the early pandemic experience. Muscle Nerve 62(4):485–491
Gupta A, Paliwal VK, Garg RK (2020) Is COVID-19-related Guillain-Barré syndrome different? Brain Behav Immun 87:177–178
Raphaël JC, Chevret S, Hughes RA, Annane D (2012) Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 7:Cd001798
Hughes RA, Swan AV, van Doorn PA (2014) Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014(9):Cd002063
Hasan I, Saif-Ur-Rahman KM, Hayat S et al (2020) Guillain-Barré syndrome associated with SARS-CoV-2 infection: a systematic review and individual participant data meta-analysis. J Peripher Nerv Syst 25(4):335–343
Schweitzer F, Kleineberg NN, Göreci Y, Onur OA, Franke C, Warnke C (2021) Neuro-COVID-19 is more than anosmia: clinical presentation, neurodiagnostics, therapies, and prognosis. Curr Opin Neurol 34(3):423–431